US Patent 10952963 Ready to use liquid RECK formulation
Patent 10952963 was granted and assigned to Quva Pharma, Inc on March, 2021 by the United States Patent and Trademark Office.
All edits
Edits on 29 May, 2024
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Edits on 12 Dec, 2023
Golden AI
Edits made to:
Article (+294 characters)
Article
Patent abstract
Disclosed herein is a ready-to-use liquid formulation comprising ropivacaine, epinephrine, clonidine, and ketorolac (collectively referred to as RECK). Also disclosed herein is a process for preparing the RECK-containing liquid formulation, as well as methods for using the same.
Edits on 9 Oct, 2023
Golden AI
Edits made to:
Infobox (+2 properties)
Infobox
Patent Inventor Names
Jianping Chen0
Travis A. Leeah0
Edits on 22 Jul, 2023
Golden AI
Edits made to:
Infobox (-1 properties)
Infobox
Official Website
Edits on 27 Apr, 2023
Golden AI
Infobox
Patent Citations
Edits on 26 Sep, 2022
Golden AI
Infobox
Is a
Patent Applicant
Current Assignee
Patent Jurisdiction
Patent Number
109529630
Date of Patent
March 23, 2021
0Patent Application Number
163814460
Date Filed
April 11, 2019
0Official Website
Patent Citations
Patent Primary Examiner
Edits on 25 Sep, 2022
Golden AI
Infobox
Patent Citations
Edits on 18 Jun, 2022
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Website URL
Edits on 10 Feb, 2022
Golden AI
Edits made to:
Infobox (+10 properties)
US Patent 10952963 Ready to use liquid RECK formulation
Infobox
Is a
Patent applicant
Current assignee
Patent jurisdiction
Patent number
10952963
Date of patent
March 23, 2021
Patent application number
16381446
Date Filed
April 11, 2019
Patent citations
Patent primary examiner
Find more entities like US Patent 10952963 Ready to use liquid RECK formulation
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
